Contribute Try STAT+ Today

Hello, everyone, and welcome to the middle of the week. Yes, we know, it can be hard to tell sometimes which day is which, but here we are. So consider it an accomplishment, given the challenges and stress confronting us all, and treat yourself to a hot cup of stimulation. A little focus is a good thing, after all. We are rifling through our stash of hazelnut, in fact. Meanwhile, here is a fresh pile of tidbits to help you along. We hope today is productive and manageable. And remember, keep on the sunny side, and keep safe…

A U.S. government-run study of remdesivir, the experimental Gilead Sciences (GILD) drug being tested to treat Covid-19, showed the medicine is effective against the novel coronavirus, STAT notes. Gilead issued a statement saying, “We understand that the trial has met its primary endpoint.” The finding — although difficult to fully characterize without any data for the study — would represent the first treatment shown to improve outcomes in patients infected with the virus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy